Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RPF08203
Bivalent RSV+HMPV protein vaccine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Safety Lead-in Cohort - Experimental | EXPERIMENTAL | Single administration of IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate |
| Safety Lead-in Cohort - Placebo | PLACEBO_COMPARATOR | Single administration of matching placebo |
| Main Cohort - Experimental | EXPERIMENTAL | Single administration of IM (intramuscular) injection of the bivalent RSV+HMPV protein vaccine candidate |
| Main Cohort - Placebo | PLACEBO_COMPARATOR | Single administration of matching placebo |
| Name | Type | Description |
|---|---|---|
| Bivalent RSV+HMPV protein vaccine | BIOLOGICAL | IM injection |
| Placebo | BIOLOGICAL | IM injection |
Inclusion Criteria: * Aged 60 years or older on the day of inclusion * Participants who, as determined by medical evaluation including medical history, physical examination, and clinical judgment of the Investigator are eligible for inclusion Exclusion Criteria: * Known/suspected immunodeficiency...
The bivalent RSV+HMPV protein vaccine is an investigational vaccine developed by Sanofi that combines respiratory syncytial virus and human metapneumovirus antigens in a single product. It is designed to protect older adults against both viruses at once. It is currently in Phase 2 clinical development and has not been approved by any regulatory agency.
It is being developed to prevent respiratory disease caused by respiratory syncytial virus and human metapneumovirus in adults 60 years of age and older. The Phase 2b trial enrolls healthy volunteers in this age group. Because the vaccine remains investigational, no approved indication has been granted.
Sanofi is developing the bivalent RSV+HMPV protein vaccine. Sanofi trades on the New York Stock Exchange under the ticker SNY. The company is running the candidate as a single combination vaccine covering two respiratory viruses rather than as separate products.
The bivalent RSV+HMPV protein vaccine is in Phase 2 development. One Phase 2b trial is currently recruiting, and no trials for this candidate have been completed. It is an investigational vaccine and is not FDA approved.
The bivalent RSV+HMPV protein vaccine is being studied in NCT07810010, a Phase 2b trial titled a study of a respiratory syncytial virus and human metapneumovirus protein vaccine candidate in adults 60 years of age and older. The trial is recruiting, plans to enroll 8,000 participants, and runs in Australia and the United Kingdom.
NCT07810010 is a randomized, double-blind, placebo-controlled Phase 2b trial of the bivalent RSV+HMPV protein vaccine. It targets 8,000 participants aged 60 years and older, includes both sexes, and enrolls healthy volunteers. The study is recruiting in Australia and the United Kingdom.